FDA Advisory Panel Backs 6 of 7 Peptides for Compounding — What the July 23–24 Vote Actually Changes

Key takeaways

On July 23–24, 2026, the FDA's Pharmacy Compounding Advisory Committee (PCAC) voted to recommend six of seven nominated peptides for Category 1 of the Section 503A Bulk Drug Substances List: BPC-157, KPV, TB-500, MOTS-c, Semax, and Epitalon. Emideltide (DSIP) failed on a 6–7 vote with one abstention. Every vote was split, and every recommendation ran against the written conclusion of the FDA's own scientific review team, which recommended against all seven. The votes are non-binding. No peptide became legal to compound on July 24 that was not legal on July 22. Category 1 placement still requires notice-and-comment rulemaking — a Notice of Proposed Rulemaking, a 60–90 day comment period, and a final rule — which published estimates put at 8 to 24 months out. The remaining five nominated peptides are scheduled for review before the end of February 2027.

The vote record

The committee reviewed each peptide against a specific proposed indication. Free base and acetate salt forms were voted separately; where forms split the same way, they are combined below.

Day one covered BPC-157, KPV, TB-500 and MOTS-c. Day two covered Emideltide, Semax and Epitalon.

Note on tallies: day-one counts are consistent across FDA Law Blog, PharmExec and RAPS. Day-two abstention counts vary slightly between outlets; the yes–no figures above follow STAT News reporting from the meeting. The official record is the FDA meeting transcript and minutes.

The unusual part: the panel overruled FDA's own reviewers

FDA's career review staff recommended against adding all seven substances. The committee approved six anyway.

The agency's central objection was not that the peptides had been shown to be dangerous. It was that FDA reviewers could not establish what, chemically, they were being asked to evaluate. FDA's Russell Wesdyk framed the BPC-157 review by asking "What is BPC-157?", noting that without a settled identity and characterization, "We cannot establish quality standards." A separate FDA remark reported from the meeting: "We've never faced a problem of, 'What is it?'" Reviewers additionally cited an absence of randomized controlled trial evidence for the proposed indications, and a thin adverse-event record — three reports for BPC-157, each confounded by concomitant medications.

Committee members split along a predictable line. Elizabeth Rebello cited the lack of efficacy data and randomized controlled trials. Bill Zamboni said there were "too many unknowns about this product." On the other side, David Pope argued for putting "this decision back in the hands of the physician and pharmacist" — an autonomy argument, not an evidence argument.

One disclosure readers should weigh directly: STAT News reported that a majority of the panelists who voted yes have ties to the peptide industry. The Dispatch has not independently verified the individual disclosures; readers evaluating the weight of this recommendation should treat that reporting as material context and consult FDA's published conflict-of-interest waivers for the meeting.

There is also a legitimate counter-argument on the record. Bob Durkin, a regulatory attorney and former member of FDA's Pharmacy Compounding Team, has argued that the material before the PCAC "show[s] that there is substantive information available about the identity and safety of each of the considered peptides," and that FDA may be applying an evidentiary standard to compounded bulk substances closer to a new-drug standard than the statute requires. Both positions are defensible. The committee's own 8–6 splits are the honest summary of where the evidence sits.

What actually changed on July 24: nothing legal

This is the part most coverage is getting wrong, and it is worth being precise about.

A PCAC vote is a recommendation, not a rule. The pathway from here has four remaining steps:

1. FDA decides whether to accept the recommendation. It is not obligated to, and it has declined advisory committee recommendations before.
2. FDA publishes a Notice of Proposed Rulemaking.
3. A public comment period runs, typically 60–90 days.
4. FDA issues a final rule placing the substance in Category 1.

Published estimates of that timeline range from roughly 8–12 months (PharmExec) to 12–24 months (Orrick). Neither the current administration's interest in the topic nor the panel's vote removes the rulemaking requirement.

The status these peptides are actually in right now

There is a widespread misconception that these peptides were "moved back to Category 1." They were not. The sequence is:

• April 15–22, 2026: FDA removed twelve peptides from Category 2 — the designation for bulk substances presenting significant safety risks, which functionally blocked their use in compounding. Those twelve: BPC-157, Cathelicidin LL-37, Dihexa acetate, Emideltide (DSIP), Epitalon, GHK-Cu (injectable routes), KPV, PEG-MGF, Melanotan II, MOTS-c, Semax, and TB-500.
• Removal from Category 2 is not placement in Category 1. FDA's interim enforcement-discretion policy extends to Category 1 substances. A substance removed from Category 2 but not yet placed in Category 1 sits outside both — no longer carrying an explicit "do not compound" designation, but not covered by enforcement discretion either.
• July 23–24, 2026: The PCAC recommended six of the seven reviewed peptides for Category 1. That recommendation is step one of four.

The accurate description of today's status is undefined middle ground, not cleared.

The constraints that survive the vote

Even in the scenario where FDA accepts all six recommendations and completes rulemaking, four limits remain in force. Anyone modeling market or clinical impact should hold these constant.

The supply-chain point deserves emphasis because it cuts against the intuitive read. Analysts covering the meeting noted that restricting these substances does not eliminate demand — it displaces demand into unverifiable supply chains, including overseas manufacturers with no meaningful quality oversight. That is the strongest public-health argument for the committee's vote, and it is an argument about channel control, not about efficacy.

What to watch next

• FDA's response to the recommendation. The agency is not bound by it. Any signal of acceptance or rejection, and the timing of an NPRM, is the next real data point.
• The February 2027 tranche. Five nominated peptides remain scheduled for PCAC review before the end of February 2027: GHK-Cu, Melanotan II, Cathelicidin (LL-37), Dihexa acetate, and PEG-MGF.
• Enforcement posture in the interim. Transition windows are historically when FDA and FTC issue warning letters. FDA sent 50+ letters to peptide sellers on September 9, 2025, and has previously described "research use only" labeling as a ruse where surrounding context implies human use. The regulatory status of a molecule and the legality of how it is marketed are separate questions.
• Marketing claims across the sector. Any operator now advertising these six peptides as "FDA approved," "FDA cleared," or "now legal" is making a claim the record does not support.

The bottom line

A divided advisory committee recommended six peptides for Category 1 over the written objection of FDA's own reviewers, with a documented industry-tie question hanging over the yes bloc. That is a meaningful shift in the direction of federal posture. It is not a change in law, and it will not be one for the better part of a year at minimum.

The Dispatch will publish an update when FDA responds to the recommendation or an NPRM appears in the Federal Register.

Sources

• FDA — July 23–24, 2026 Meeting of the Pharmacy Compounding Advisory Committee: https://www.fda.gov/advisory-committees/advisory-committee-calendar/july-23-24-2026-meeting-pharmacy-compounding-advisory-committee-07232026
• FDA Law Blog — PCAC Approves Four Bulk Drug Substances for the 503A List: https://www.thefdalawblog.com/2026/07/peptide-l-wave-pcac-approves-four-bulk-drug-substances-for-the-503a-list/
• FDA Law Blog — FDA's Pep(tide) Rally! What Compounders and Industry Need to Know: https://www.thefdalawblog.com/2026/04/fdas-peptide-rally-what-compounders-and-industry-need-to-know-post-1-of-2/
• Frier Levitt — FDA to Remove 12 Popular Peptides from the Category 2 "Do Not Compound" List: https://www.frierlevitt.com/articles/fda-peptides-do-not-compound-list-update-2026/
• RAPS — FDA advisory committee backs two controversial peptides: https://www.raps.org/resource/fda-advisory-committee-backs-two-controversial-peptides.html
• PharmExec — FDA Panel Votes to Loosen Restrictions for Four Peptides: https://www.pharmexec.com/view/fda-votes-loosen-restrictions-four-peptides
• STAT News — FDA panel backs compounded BPC-157, KPV peptides: https://www.statnews.com/2026/07/23/fda-panel-okays-peptides-compound-pharmacies-bpc-157-kpv/
• STAT News — FDA advisory panel narrowly rejects compounding of one peptide, backs two others: https://www.statnews.com/2026/07/24/fda-peptide-compounding-panel-backs-epitalon-rejects-emideltide/
• Orrick — FDA Peptide Compounding Vote: What to Watch at the July PCAC Meeting: https://www.orrick.com/en/Insights/2026/07/FDA-Peptide-Compounding-Vote-What-to-Watch-at-the-July-PCAC-Meeting
• NutraIngredients — FDA peptide panel raises questions about future dietary supplement pathway: https://www.nutraingredients.com/Article/2026/07/27/fda-peptide-panel-raises-questions-about-future-dietary-supplement-pathway/

The Peptide Dispatch is an editorially independent research and education publication, commonly owned with 1836 Wellness LLC. This article is educational and does not constitute medical advice. It is not a recommendation to use, obtain, or compound any substance. The Peptide Dispatch is not a pharmacy, vendor, or prescriber. Consult a licensed provider before starting, modifying, or stopping any protocol. Intended for an audience of 18+ engaged in research and education.